Identification of Altered Transcripts and Pathways in Triple Negative Breast Cancer

Kuzņecova, Elza; Daneberga, Zanda; Berga-Švītiņa, Egija; Nakazawa-Miklaševiča, Miki; Irmejs, Arvīds; Gardovskis, Jānis; Miklaševičs, Edvīns

doi:10.2478/prolas-2023-0004

Abstract

Triple negative breast cancer (TNBC) is a breast cancer subtype characterised by lack of oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor, and by worse prognosis than other cancer types. The aim of this study was to identify hub genes and molecular pathways for possible prognostic markers for TNBC. Nineteen breast cancer transcriptomes were sequenced using Illumina platform and analysed to identify differentially expressed genes in the TNBC subtype. Gene ontology enrichment analysis was conducted using the ToppGene tool. Then, the STRING online database was used for protein-protein interaction (PPI) network construction. Cytohubba and the MCODE plug-in were used to screen functional modules and hub genes. In total, 229 DEGs were identified by differential gene expression analysis in the TNBC group. Eight genes were screened out from the PPI network — FOXA1, ESR1, TFF1, GATA3, TFF3, AR, SLC39A6, COL9A1. In conclusion, this study indicates that the molecular subtype specific gene expression pattern provides useful information for targeted, biomarker-driven treatment options.

References

Albergaria, A., Paredes, J., Sousa, B., Milanezi, F., Carneiro, V., Bastos, J., Costa, S., Vieira, D., Lopes, N., Lam, E. W., Lunet, N., Schmitt, F. (2009). Expression of FOXA1 and GATA-3 in breast cancer: The prognostic significance in hormone receptor-negative tumours. Breast Cancer Res., 11 (3), R40. DOI: 10.1186/bcr2327. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716509/.
Search in Google Scholar Back to article
Asano, Y., Kashiwagi, S., Goto, W., Tanaka, S., Morisaki, T., Takashima, T., Noda, S., Onoda, N., Ohsawa, M., Hirakawa, K., Ohira, M. (2017). Expression and clinical significance of androgen receptor in triple-negative breast cancer. Cancers, 9 (1), 4. DOI: 10.3390/cancers9010004. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295775/.
Search in Google Scholar Back to article
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., Gianni, L. (2016). Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol., 13 (11), 674–690. https://doi.org/10.1038/nrclinonc.2016.66.10.1038/nrclinonc.2016.66546112227184417
Search in Google Scholar Back to article
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., Mills, G. B., Lau, C. C., Brown, P. H. (2015). Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res., 21 (7), 1688–1698. DOI: 10.1158/1078-0432.CCR-14-0432. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362882/.
Search in Google Scholar Back to article
Chin, C. H., Chen, S. H., Wu, H. H., Ho, C. W., Ko, M. T., Lin, C. Y. (2014). cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol., 8 (Suppl 4), S11. https://doi.org/10.1186/1752-0509-8-S4-S11.10.1186/1752-0509-8-S4-S11429068725521941
Search in Google Scholar Back to article
Chen, J., Bardes, E., Aronow, B., Jegga, A. (2009). ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucl. Acids Res., 37, W305-11. DOI: 10.1093/nar/gkp427. https://www.researchgate.net/publication/26236961_ToppGene_Suite_for_gene_list_enrichment_analysis_and_candidate_gene_prioritization.
Search in Google Scholar Back to article
Cimino-Mathews, A., Subhawong, A. P., Elwood, H., Warzecha, H. N., Sharma, R., Park, B. H., Taube, J. M., Illei, P. B., Argani, P. (2013). Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Hum. Pathol., 44 (6), 959–965. DOI: 10.1016/j.humpath.2012.09.005. https://pubmed.ncbi.nlm.nih.gov/23260325/.10.1016/j.humpath.2012.09.005397817823260325
Search in Google Scholar Back to article
Collins, L. C., Cole, K. S., Marotti, J. D., Hu, R., Schnitt, S. J., Tamimi, R. M. (2011). Androgen receptor expression in breast cancer in relation to molecular phenotype: Results from the Nurses’ Health Study. Mod. Pathol., 24 (7), 924–931. https://www.nature.com/articles/modpathol201154#ethics.
Search in Google Scholar Back to article
Dai, X., Cheng, H., Chen, X., Li, T., Zhang, J., Jin, G., Cai, D., Huang, Z. (2019). FOXA1 is prognostic of triple negative breast cancers by transcriptionally suppressing SOD2 and IL6. Int. J. Biol. Sci., 15 (5), 1030–1041. DOI: 10.7150/ijbs.31009. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535797/.
Search in Google Scholar Back to article
Dong, P., Yu, B., Pan, L., Tian, X., Liu, F. (2018). Identification of key genes and pathways in triple-negative breast cancer by integrated bioinformatics analysis. BioMed Res. Int., 2018, 2760918. DOI: org/10.1155/2018/2760918. https://www.hindawi.com/journals/bmri/2018/2760918/.
Search in Google Scholar Back to article
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., Bray, F. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer, 144 (8), 1941–1953. https://doi.org/10.1002/ijc.31937.10.1002/ijc.3193730350310
Search in Google Scholar Back to article
Gerratana, L., Basile, D., Buono, G., De Placido, S., Giuliano, M., Minichillo, S., Coinu, A., Martorana, F., De Santo, I., Del Mastro, L., De Laurentiis, M., Puglisi, F., Arpino, G. (2018). Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treat. Rev., 68, 102–110. https://doi.org/10.1016/j.ctrv.2018.06.005.10.1016/j.ctrv.2018.06.00529940524
Search in Google Scholar Back to article
Gucalp, A., Traina, T. A. (2010). Triple-negative breast cancer: Role of the androgen receptor. Cancer J. (Sudbury, Mass.), 16 (1), 62–65. DOI: 10.1097/PPO.0b013e3181ce4ae1. https://pubmed.ncbi.nlm.nih.gov/20164692/.20164692
Open DOI Search in Google Scholar Back to article
Guiu, S., Mollevi, C., Charon-Barra, C., Boissičre, F., Crapez, E., Chartron, E., Lamy, P. J., Gutowski, M., Bourgier, C., Romieu, G., Simony-Lafontaine, J., Jacot, W. (2018). Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. Brit. J. Cancer, 119 (1), 76–79. DOI: 10.3390/cancers13040765. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918092/.791809233673133
Open DOI Search in Google Scholar Back to article
Gupta, P. B., Kuperwasser, C. (2006). Contributions of estrogen to ER-negative breast tumor growth. J. Steroid Biochem. Mol. Biol., 102 (1–5), 71–78. DOI: 10.1016/j.jsbmb.2006.09.025. PMID: 17049443. https://www.sciencedirect.com/science/article/pii/S0960076006002706?via%3Dihub.17049443
Open DOI Search in Google Scholar Back to article
Hwang, K. T., Kim, J., Jung, J., Chang, J. H., Chai, Y. J., Oh, S. W., Oh, S., Kim, Y. A., Park, S. B., Hwang, K. R. (2019). Impact of breast cancer sub-types on prognosis of women with operable invasive breast cancer: A population-based study using SEER Database. Clin. Cancer Res., 25 (6), 1970–1979. https://doi.org/10.1158/1078-0432.CCR-18-2782.10.1158/1078-0432.CCR-18-278230559169
Search in Google Scholar Back to article
Haffty, B. G., Yang, Q., Reiss, M., Kearney, T., Higgins, S. A., Weidhaas, J., Harris, L., Hait, W., Toppmeyer, D. (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol., 24 (36), 5652–5657. DOI: 10.1200/JCO.2006.06.5664. https://ascopubs.org/doi/10.1200/JCO.2006.06.5664?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.17116942
Open DOI Search in Google Scholar Back to article
Ishibashi, Y., Ohtsu, H., Ikemura, M., Kikuchi, Y., Niwa, T., Nishioka, K., Uchida, Y., Miura, H., Aikou, S., Gunji, T., et al. (2017). Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer. Sci. Rep., 7 (1), 4846. DOI: 10.1038/s41598-017-05129-y. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501858/.550185828687783
Open DOI Search in Google Scholar Back to article
Jamidi, S. K., Hu, J., Aphivatanasiri, C., Tsang, J. Y., Poon, I. K., Li, J. J., Chan, S. K., Cheung, S. Y., Tse, G. M. (2020). Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer. Histopathology, 77 (6), 936–948. https://doi.org/10.1111/his.14118.10.1111/his.1411832304249
Search in Google Scholar Back to article
Kesson, E. M., Allardice, G. M., George, W. D., Burns, H. J., Morrison, D. S. (2012). Effects of multidisciplinary team working on breast cancer survival: Retrospective, comparative, interventional cohort study of 13 722 women. Brit. Med. J. (Clin. Res. ed.), 344, e2718. https://doi.org/10.1136/bmj.e2718.10.1136/bmj.e2718333987522539013
Search in Google Scholar Back to article
Kim, S., Moon, B. I., Lim, W., Park, S., Cho, M. S., Sung, S. H. (2016). Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer. Hum. Pathol., 55, 190–195. https://doi.org/10.1016/j.humpath.2016.04.013. https://www.sciencedirect.com/science/article/abs/pii/S0046817716300624?via%3Dihub.
Search in Google Scholar Back to article
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., Pietenpol, J. A. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig., 121 (7), 2750–2767. DOI: 10.1172/JCI45014. https://www.jci.org/articles/view/45014.312743521633166
Open DOI Search in Google Scholar Back to article
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., Pietenpol, J. A. (2016). Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PloS One, 11 (6), e0157368. DOI: 10.1371/journal.pone.0157368. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4911051/.491105127310713
Open DOI Search in Google Scholar Back to article
Li, L., Huang, H., Zhu, M., Wu, J. (2021). Identification of hub genes and pathways of triple negative breast cancer by expression profiles analysis. Cancer Manag. Res., 13, 2095–2104. DOI: 10.2147/CMAR.S295951. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935333/.793533333688252
Open DOI Search in Google Scholar Back to article
Liu, Z., Chen, S. (2010). ER regulates an evolutionarily conserved apoptosis pathway. Biochem. Biophys. Res. Comm., 400 (1), 34–38. DOI: 10.1016/j.bbrc.2010.07.132. https://www.sciencedirect.com/science/article/abs/pii/S0006291X10014658?via%3Dihub.20691160
Open DOI Search in Google Scholar Back to article
Madsen, J., Nielsen, O., Torn¸e, I., Thim, L., Holmskov, U. (2007). Tissue localization of human trefoil factors 1, 2, and 3. J. Histochem. Cytochem., 55 (5), 505–513. DOI: 10.1369/jhc.6A7100.2007. https://journals.sagepub.com/doi/10.1369/jhc.6A7100.2007?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.17242463
Open DOI Search in Google Scholar Back to article
Malorni, L., Shetty, P. B., De Angelis, C., Hilsenbeck, S., Rimawi, M. F., Elledge, R., Osborne, C. K., De Placido, S., Arpino, G. (2012). Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res. Treat., 136 (3), 795–804. DOI: 10.1007/s10549-012-2315-y. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513514/.351351423124476
Open DOI Search in Google Scholar Back to article
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., Symmans, W. F., Ueno, N. T. (2013). Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin. Cancer Res., 19 (19), 5533–5540. DOI: 10.1158/1078-0432.CCR-13-0799. https://clincancerres.aacrjournals.org/content/19/19/5533.381359723948975
Open DOI Search in Google Scholar Back to article
Mehra, R., Varambally, S., Ding, L., Shen, R., Sabel, M. S., Ghosh, D., Chinnaiyan, A. M., Kleer, C. G. (2005). Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res., 65 (24), 11259–11264. DOI: 10.1158/0008-5472.CAN-05-2495. https://cancerres.aacrjournals.org/content/65/24/11259.long.16357129
Open DOI Search in Google Scholar Back to article
Mrklić, I., Pogorelić, Z., Capkun, V., Tomić, S. (2013). Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem., 115 (4), 344–348. DOI: 10.1016/j.acthis.2012.09.006. https://www.sciencedirect.com/science/article/abs/pii/S0065128112001158?via%3Dihub.23031358
Open DOI Search in Google Scholar Back to article
Nallanthighal, S., Heiserman, J. P., Cheon, D. J. (2019). The role of the extracellular matrix in cancer stemness. Frontiers Cell Devel. Biol., 7, 86. https://doi.org/10.3389/fcell.2019.00086.10.3389/fcell.2019.00086662440931334229
Search in Google Scholar Back to article
Reis-Filho, J. S., Pusztai, L. (2011). Gene expression profiling in breast cancer: Classification, prognostication, and prediction. Lancet, 378, 1812–1823. DOI: 10.1016/S0140-6736(11)61539-0. https://pubmed.ncbi.nlm.nih.gov/22098854/.22098854
Open DOI Search in Google Scholar Back to article
Sartorius, C. A., Hanna, C. T., Gril, B., Cruz, H., Serkova, N. J., Huber, K. M., Kabos, P., Schedin, T. B., Borges, V. F., Steeg, P. S., Cittelly, D. M. (2016). Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene, 35 (22), 2881–2892. DOI: 10.1038/onc.2015.353. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809801/.480980126411365
Open DOI Search in Google Scholar Back to article
Shaoxian, T., Baohua, Y., Xiaoli, X., Yufan, C., Xiaoyu, T., Hongfen, L., Rui, B., Xiangjie, S., Ruohong, S., Wentao, Y. (2017). Characterisation of GATA3 expression in invasive breast cancer: Differences in histological subtypes and immunohistochemically defined molecular subtypes. J. Clin. Pathol., 70 (11), 926–934. https://jcp.bmj.com/content/70/11/926.long.10.1136/jclinpath-2016-20413728428285
Search in Google Scholar Back to article
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA, 98 (19), 10869–10874. DOI: 10.1073/pnas.191367098. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC58566/.5856611553815
Open DOI Search in Google Scholar Back to article
Yi, J., Ren, L., Li, D., Wu, J., Li, W., Du, G., Wang, J. (2020). Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers. Biomed. Pharmacother., 124, 109827. DOI: 10.1016/j.biopha.2020.109827. https://www.sciencedirect.com/science/article/pii/S0753332220300172.31986408
Open DOI Search in Google Scholar Back to article

Identification of Altered Transcripts and Pathways in Triple Negative Breast Cancer

Abstract

Paradigm

My account